What consideration has the Welsh Government given to the establishment of a patient access scheme for Liothyronine in Wales?
The Welsh Government has given no consideration to establishing a patient access scheme (PAS) for liothyronine.
PAS arrangements are made under the 2019 Voluntary Scheme for Branded Medicines Pricing and Access. A PAS proposes a discount, rebate or other variation from the list price of a branded medicine when it is purchased by the NHS. Liothyronine is a generic medicine, the price of which is determined by its manufacturer, with the cost of liothyronine to the NHS reflecting the price its manufacturers charge suppliers such as pharmacies.